Very recently, Pellefigues et al. suggested that antagonizing PTGDR-1 and -2 (prostaglandin D2 receptors), by using laropiprant and ramatroban (two FDA-approved drugs for the treatment of some forms of dyslipidemia and allergic rhinitis, respectively) in human lupus, might be a quick and accessible therapeutic resource [48]. The gene discussed is PTGDR; the disease is metabolic syndrome.